Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05361382
PHASE1

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

Sponsor: Tharick Pascoal

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates.

Official title: Longitudinal Multicenter Head-to-Head Harmonization of Tau PET Tracers

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

822

Start Date

2022-03-02

Completion Date

2027-05-31

Last Updated

2025-10-29

Healthy Volunteers

Yes

Interventions

DRUG

18F-Flortaucipir radiopharmaceutical

Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.

DRUG

18F-MK-6240 radiopharmaceutical

MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.

DRUG

Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)

The clinical sites will use either PiB, Florbetaben, Flutemetamol, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques. Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the Flutemetamol radiopharmaceutical.

Locations (9)

Lawrence Berkeley National Laboratory

Berkeley, California, United States

University of California San Francisco

San Francisco, California, United States

Mayo Clinic

Rochester, Minnesota, United States

Washington University in St. Louis

St Louis, Missouri, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Brown University

Providence, Rhode Island, United States

Houston Methodist Neurological Institute

Houston, Texas, United States

McGill University

Montreal, Quebec, Canada

Sant Pau Biomedical Research Institute

Barcelona, Spain, Spain